Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a pioneering biopharmaceutical company focused on the development of innovative antiviral therapeutics. Led by a team of experienced professionals, Chimerix aims to enhance the quality of life for patients across diverse medical fields, including transplant, oncology, acute care, and global health.
Chimerix leverages its proprietary lipid technology, resulting in two promising clinical-stage compounds: CMX001 and CMX157. These compounds have shown potential for improved activity, bioavailability, and safety over existing drugs. The lead compound, CMX001, is a broad-spectrum antiviral that combats double-stranded DNA (dsDNA) viruses, such as cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus, and variola (smallpox). CMX001 has completed Phase 2 development for CMV prophylaxis and is currently in Phase 2 trials for adenovirus treatment in hematopoietic stem cell transplant (HSCT) recipients.
Chimerix’s portfolio also includes ONC201, an oral, first-in-class small molecule imipridone targeting H3 K27M-mutant gliomas. The Phase 3 ACTION trial for ONC201 is a major focus, enrolling patients at over 130 sites in 13 countries. This study aims to report interim overall survival data by early 2025. Additionally, Chimerix's second-generation compound, ONC206, is undergoing Phase I dose escalation trials, demonstrating anti-cancer activity in both CNS and non-CNS tumors.
Financially, Chimerix maintains a robust balance sheet with significant capital to fund ongoing operations, reflecting sound fiscal management. The company reported a net loss of $18.6 million for Q2 2023 but continues to advance its research and development initiatives.
Chimerix’s mission is to develop medications that significantly improve and extend the lives of patients battling severe diseases. With ongoing clinical trials, strategic financial planning, and a dedicated team, Chimerix is poised to make substantial contributions to global health.
Chimerix (CMRX) announces plans to submit a New Drug Application (NDA) for dordaviprone to the FDA before year-end, seeking accelerated approval for treating recurrent H3 K27M-mutant diffuse glioma. The company anticipates potential approval by Q3 2025, pending Priority Review.
The submission follows productive FDA interactions and includes key data showing a 28% objective response rate, 10.4-month median duration of response, and 4.6-month median time to response under RANO 2.0 criteria. Dordaviprone could become the first FDA-approved therapy for this rare disease affecting over 2,000 U.S. patients annually.
The drug has received Rare Pediatric Disease Designation and is eligible for a Priority Review Voucher. Chimerix is preparing for potential U.S. launch as early as Q3 2025.
Chimerix (NASDAQ:CMRX) has announced that its Compensation Committee granted inducement awards to three new employees on December 2, 2024. The awards consist of non-statutory stock options to purchase up to 385,000 shares of common stock. The options have a 10-year term with an exercise price equal to Chimerix's closing trading price on the grant date.
The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. While subject to the terms of Chimerix's 2024 Equity Incentive Plan, these grants were made outside of it. The company, focused on developing medicines for deadly diseases, is currently advancing dordaviprone (ONC201) for H3 K27M-mutant glioma and conducting Phase 1 studies of ONC206.
Chimerix (NASDAQ: CMRX) announced updated Phase 2 response assessment results for dordaviprone in treating recurrent H3 K27M-mutant diffuse midline glioma. Using the new RANO 2.0 criteria, the treatment showed a 28.0% overall response rate, with a median time to response of 4.6 months and a median duration of response of 10.4 months. The company plans to include these updated results in their upcoming New Drug Application to Australian regulators. The findings will be presented at the 2024 Society for Neuro-Oncology Annual Meeting in Houston, along with additional pipeline presentations.
Chimerix (NASDAQ: CMRX) reported Q3 2024 financial results with a net loss of $22.9 million ($0.26 per share), compared to $24.0 million ($0.27 per share) in Q3 2023. Research and development expenses increased to $19.6 million from $17.4 million year-over-year, while general and administrative expenses decreased to $5.2 million from $9.3 million.
The company's Phase 3 ACTION study for dordaviprone remains on track with first interim Overall Survival data expected in Q3 2025. The Independent Data Monitoring Committee recommended continuing the study as planned. Chimerix ended Q3 with $152.4 million in available capital and plans to submit a New Drug Application for Provisional Approval in Australia in the coming months.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on developing life-saving medicines, has scheduled a conference call and audio webcast for November 7, 2024, at 8:30 a.m. ET. During this event, the company will present its third quarter 2024 financial results and provide a business update. Participants can join via phone at (646) 307-1963 (domestic) or (800) 715-9871 (international) using conference ID 6580777. A live webcast will be available on the company's website, with an archived version accessible approximately two hours after the event.
Chimerix (NASDAQ:CMRX) announced that on October 16, 2024, its Compensation Committee granted an inducement award to a new employee. The award consists of non-statutory stock options to purchase up to 130,000 shares of Chimerix's common stock. This grant was approved as an inducement material to the new employee's employment, in accordance with Nasdaq Listing rule 5635(c)(4).
The stock options have an exercise price equal to Chimerix's closing trading price on the grant date, a 10-year term, and will vest over four years. One-fourth will vest on the one-year anniversary of the hire date, with the remaining three-fourths vesting in equal monthly installments over the following three years. While subject to the terms of Chimerix's 2024 Equity Incentive Plan, these options were granted outside of it.
Chimerix is a biopharmaceutical company focused on developing medicines for deadly diseases. Their most advanced clinical-stage program, ONC201, is being developed for H3 K27M-mutant glioma. The company is also conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Mike Andriole, the company's CEO, will deliver a corporate presentation on September 9, 2024, at 7:00 a.m. ET.
The presentation will be made available as an audio webcast on the Investor Relations section of Chimerix's website at ir.chimerix.com. Interested parties can access the webcast, which will remain archived on the site for approximately 90 days. This event provides an opportunity for investors and analysts to gain insights into Chimerix's latest developments and future strategies.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced on August 30, 2024, that its Compensation Committee granted an inducement award to a new employee. The award consists of non-statutory stock options to purchase up to 150,000 shares of Chimerix's common stock. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of hire and the remaining three-fourths vesting monthly over the following three years. The exercise price is equal to Chimerix's closing trading price on the grant date. This award was approved in accordance with Nasdaq Listing rule 5635(c)(4) and is subject to the terms of Chimerix's 2024 Equity Incentive Plan, although granted outside of it.
Chimerix (NASDAQ: CMRX) reported Q2 2024 financial results and provided an operational update. Key highlights include:
- Phase 3 ACTION study for dordaviprone on track with first interim overall survival data expected in Q3 2025
- ONC206 Phase 1 trials showing promising PK and safety data
- Dordaviprone filed for Provisional Determination in Australia
- Q2 2024 net loss of $20.7 million, or $0.23 per share
- Research and development expenses increased to $18.4 million
- Cash balance of $171.5 million as of June 30, 2024
The company continues to advance its pipeline, focusing on dordaviprone for H3 K27M-mutant diffuse glioma and ONC206 for various CNS tumors.
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on developing medicines for deadly diseases, has announced it will host a live conference call and audio webcast on August 13, 2024, at 8:30 a.m. ET. The purpose of this event is to report financial results for the second quarter ended June 30, 2024, and provide a business overview.
Interested parties can access the call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) and referring to conference ID 5436125. A live audio webcast will be available on the Investors' section of Chimerix's website, with an archived version accessible approximately two hours after the event.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
What does Chimerix, Inc. do?
What are Chimerix's leading compounds?
What stages are Chimerix's clinical trials in?
How is Chimerix financially positioned?
What is the significance of the ONC201 Phase 3 ACTION trial?
What kind of partnerships does Chimerix have?
Where is Chimerix based?
How does Chimerix generate revenue?
What is unique about Chimerix’s lipid technology?
What is Chimerix's mission?
